A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

Summary

This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).

Timeline

Start

2013-06

Primary completion

2016-08

Completion

2018-08

Publications

• Fleseriu M, Biller BMK, Webb SM, Strasburger CJ, Georgescu CE, Bidlingmaier M, Wang C, Baciu I, Casanueva FF, Gilis-Januszewska A, Hart G, Manners A, Choe J, Bar-Ilan A, Carlsson M, Torre D, Taylor CT, Yuen KCJ. Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study. Pituitary. 2026 Mar 25;29(2):59. doi: 10.1007/s11102-026-01661-1.

Drugs

Indications